Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Merus N.V. (MRUS) Report Negative Q1 Earnings?

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Meeting 2024.

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Gilead Sciences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the use of Merus' proprietary Triclonics® platform along with Gilead's oncology expertise to research and develop multiple, separate preclinical research programs. Merus is a clinical-stage onco.

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Merus N.V. results from the phase 1/2 eNRGy trial, using zenocutuzumab for the treatment of patients with NRG1+ PDAC and NSCLC, are expected in the 1st half of 2024. Should results from the phase 1/2 eNRGy trial turn out to be positive, then Merus will be able to file BLA of zenocutuzumab for the treatment of patients NRG1+cancers. Petosemtamab is another clinical candidate being advanced in the pipeline for the treatment of both 1st-line and 2nd-line HNSCC; Data for each program targeting such populations is expected in 2024.

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:

Merus to Participate in Upcoming Investor Conferences

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Merus N.V. (MRUS) Surges 16.3%: Is This an Indication of Further Gains?

The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 52.96% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, showed promising results in a phase 1/2 trial for head and neck cancer, with an objective response rate of 35.7%. Zenocutuzumab, targeting HER2/HER3 in NRG1-positive NSCLC and pancreatic cancer, demonstrated an overall response rate of 37.2% and 42.4%.

Merus: (Maybe) Building A Better Bispecific

The mean of analysts' price targets for Merus N.V. (MRUS) points to an 87.7% upside in the stock.

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 87.71%: Read This Before Placing a Bet

Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Merus N.V. (MRUS) Moves to Buy: Rationale Behind the Upgrade

MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24 MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

-  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

The average of price targets set by Wall Street analysts indicates a potential upside of 85.4% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See an 85.36% Upside in Merus N.V. (MRUS): Can the Stock Really Move This High?

The consensus price target hints at an 83.3% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Merus N.V. (MRUS) Could Surge 83.26%: Read This Before Placing a Bet

– Petosemtamab in combination with Keytruda 1L initial interim clinical data planned for 1H24; 2L+ HNSCC monotherapy clinical update planned 2024

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

- 37% ORR and 14.9 months median DOR in 78 evaluable NRG1+ NSCLC patients - 42% ORR and 9.1 months median DOR in 33 evaluable NRG1+ PDAC patients - Sufficient clinical data expected in 1H24 to support potential BLA submissions UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Merus N.V.

Merus' Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m. ET.

Merus Announces Business Update Conference Call

Mini Oral: MCLA-129 in combination with osimertinib in treatment naïve, and after progression on osimertinib, non-small cell lung cancer

Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the stock is mixed and price structure has broken down. Updates from its major clinical programs are the key drivers to equity returns for MRUS at this stage in its lifecycle.

Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 1,022,727 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $150.0 million. All of the shares in the offering are to be sold by Merus.

Merus Announces Pricing of Public Offering of Common Shares

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.13 per share a year ago.

News for Merus Stock (MRUS)